The ASCO Pre-Annual Meeting Seminar is a multi-disciplinary seminar that will be hosted by the American Society of Clinical Oncology (ASCO) and co-sponsored by the Society for Immunotherapy of Cancer (SITC). "ImmunOcology: Effectively Integrating Immunotherapy into Today's Clinical Practice" and will be held in the afternoon on Thursday, May 30, 2019 and the morning of Friday, May 31, 2019.
Advances in cancer immunotherapy research are rapidly emerging, with an increasing rate of new approvals for the routine clinical use of immunotherapy agents in the clinic across a variety of cancers. The pace of progress in the field necessitates the continuing education of oncology clinicians to enable them to provide the most up-to-date and comprehensive immunotherapy-based treatment options to their patients. In addition, oncologists, nurses and pharmacists with basic knowledge related to utilizing immunotherapy in clinical practice continue to be challenged by issues related to patient selection and toxicity management.
This seminar is approved for physician, nursing, and pharmacist continuing education credits.
ImmunOcology: Effectively Integrating Immunotherapy into Today's Clinical PracticeSeminar Committee
Co-Chairs: Leisha Emens, MD, PhD* –
University of Pittsburgh Medical Center
Ravi Madan, MD
– National Cancer Institute/National Institute of HealthStephen Ansell, MD, PhD
– Mayo ClinicDoreen Higgins, RN, BSN, CCRP –
University of WashingtonTanguy Seiwert, MD*
– University of ChicagoMario Sznol, MD* –
Yale School of MedicineEleni Yeatras, RPh, BCOP* –
US Oncology Research
*Denotes SITC MemberImmunOncology: Effectively Integrating Immunotherapy into Today's Clinical Practice
Program Agenda
Day One: 12:30 p.m. - 5:00 p.m. Thursday, May 30, 2019
12:30 – 1:00 p.m.
|
Lunch
|
Session 1: The Biology and Biomarkers of Immunotherapy
|
1:00 – 1:30 p.m.
|
The Biology and Biomarkers of Immunotherapy Tanguy Seiwert, MD* – University of Chicago
|
Session 2: Integrating Immunotherapy into Clinical Practice – Changers Over the Past Year (Part 1)
|
1:30 – 3:20 p.m.
|
Lung Cancer (Non-Small Cell) Vamsidhar Velcheti, MD, FACP – NYU Langone, Perlmutter Cancer Center
Breast and Gynecologic Cancers Leisha Emens, MD* – University of Pittsburgh Medical Center
Melanoma/Skin Cancers Jose Lutzky, MD* – Mount Sinai Medical Center
Head and Neck Cancers Priscila Goncalves, MD* – Northwell Health
|
3:20 – 3:35 p.m.
|
Break
|
Session 3: Integrating Immunotherapy into Clinical Practice – Changers Over the Past Year (Part 2)
|
3:35 – 5:00 p.m.
|
Gastrointestinal Malignancies Michael Overman, MD – University of Texas MD Anderson Cancer Center
Genitourinary Malignancies Petros Grivas, MD, PhD – University of Washington
Hematologic Malignancies Pier Luigi Zinzani, MD, PhD – Institute of Hematology Seragnoli, University of Bologna
|
Day Two: 7:30 a.m. - 11:00 a.m. Friday, May 31, 2019
7:00 – 7:30 a.m.
|
Breakfast
|
Session 4: Managing Immune Toxicities: A Case-Based Discussion with Experts
|
7:30 – 9:00 a.m.
|
Neuro-Oncologist’s Perspective David A. Reardon, MD – Dana-Farber Cancer Institute
Dermatologist’s Perspective Jennifer Choi, MD* – Northwestern University Feinberg School of Medicine
Gastrointestinal Oncologist’s Perspective Shilpa Grover, MD – Brigham and Women’s Hospital
Hematologic Oncologist’s Perspective Hongtau Liu, MD, PhD – University of Chicago
Rheumatologist’s Perspective Lenore Buckley, MD, MPHD – Yale School of Medicine
|
9:00 – 9:15 a.m.
|
Break
|
Session 5: Hyper-Progression: Myth or Reality?
|
9:15 – 10:10 a.m.
|
Data Supports that Hyper-Progression is Real Aurelian Marabelle, MD, PhD – Gustave Roussy
Data Supports that Hyper-Progression is a Myth Alexander Pearson, MD, PhD – University of Chicago
|
Session 6: Moving Forward – Beyond Immune Checkpoint Inhibitors
|
10:10 – 11:00 a.m.
|
Next Generation Immunotherapy: Immunocytokines and Oncolytic Viruses Evanthia Galanis, MD – Mayo Clinic
CAR-T Cells: What’s Next? Jeremy Abramson, MD – Massachusetts General Hospital Cancer Center, Harvard Medical School
|
*Denotes SITC Member
For more information, or to register, please click
here.
#ClinicalTrials#CME#CNE#CPE#BladderCancer#BreastCancers#Colon Cancer
#GastrointestinalCancers#GenitourinaryCancers#GynecologicCancers#HeadandNeckCancers#HematologicMalignancies#LungCancers#Melanoma#Non-SmallCellLungCancer#SkinCancers#RenalCellCarcinoma#InPersonEvent#Collaboration#SITC#AdverseEvents#Toxicities#Clinician#NursePractitioner#Oncologist#Pharmacist#Physician#PhysicianAssistant#RegisteredNurse#2019